Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The FDA has approved PrandiMet (repaglinide and metformin HCl tablets, from Sciele and Novo Nordisk) as an adjunct to diet and exercise in type 2 diabetes when response to repaglinide or metformin monotherapy is inadequate. This approval was based on data demonstrating that PrandiMet was bioequivalent to corresponding doses of repaglinide and metformin as individual tablets.
PrandiMet is expected to be available during the second half of 2008 in 1mg/500mg and 2mg/500mg dosage strengths.
For more information call (888) NOVO-444 or visit www.prandimet.com.
Related Content
